Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare form of skin lymphoma that is localized primarily to the subcutaneous adipose tissue without involvement of the lymph nodes. Clinically, the skin lesions mimic lipomas, while histologically they resemble panniculitis. We report a case of a young woman with SPTCL. She achieved complete remission after combination chemotherapy.
S ubcutaneous panniculitis-like T-cell lymphoma (SPTCL), a rare form of skin lymphoma, preferentially infi ltrates the subcutaneous adipose tissue. In 2008, it was categorized as a type of mature T-cell and natural killer cell lymphoma ( 1 ). We report a young woman who presented with multiple subcutaneous lesions and was diagnosed with SPTCL.
CASE DESCRIPTION
A 25-year-old woman presented with painless papulonodular skin lesions in the abdomen, chest, and limbs. Th e lesions had appeared 18 months earlier. She had a low-grade intermittent fever, had a poor appetite, and had lost 5 kg over the past 6 months. She had painless nodular subcutaneous skin lesions 1 to 2 cm in size involving all four limbs and the chest and abdomen (Figure 1a) . Th e nodules were painless and erythematous. She had no other symptoms, organomegaly, or lymphadenopathy. A computed tomography scan showed subcutaneous soft tissue thickening with fat stranding in the upper chest, anterior abdominal wall, and upper arm bilaterally. T1-and T2-weighted magnetic resonance imaging of both arms showed intermediate-signal-intensity lesions in the skin and subcutaneous plane (Figure 1b ) . Th ese lesions showed heterogeneous postcontrast enhancement, and underlying muscles showed normal signal intensities. Histopathological examination of a skin biopsy showed the subcutaneous tissue infi ltrated by a neoplasm composed of atypical lymphoid cells with medium size scanty cytoplasm and a round nucleus with fi ne chromatin and small nucleoli. Angioinvasion was also present (Figure 2a ) . On immunohistochemistry, the tumor cells were positive for CD3, CD8, perforin, and granzyme and were negative for CD20, CD4, and CD56 (Figure 2b, 2c) . Th e picture was diagnostic of SPTCL. Her hemoglobin was 8.8 g/dL; total leukocyte count, 5000/mm 3 ; platelet count, 327000 /mm 3 ; and erythrocyte sedimentation rate, 80 mm/1st hour. Her renal function, liver function, and serum electrolytes were normal. Her serum lactate dehydrogenase level was 1407 IU/L. A bone marrow study was normal. She was started on chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Her skin lesions resolved after two courses, and she completed six courses of chemotherapy. At present, she is alive and in complete remission 18 months after therapy.
DISCUSSION
SPTCL is a rare tumor of T-cell origin representing <1% of all non-Hodgkin's lymphomas ( 2 ) . It was fi rst described Th e disease typically follows a distinctive, indolent course of recurrent, self-healing subcutaneous nodules. Often it presents as multiple painless subcutaneous nodules on the extremities and trunk. In its early phase, the nodules may resolve without treatment and new nodules may develop on the same or diff erent skin locations. Diagnosis of SPTCL is a challenge, especially in the early stages when the symptoms mimic other more common conditions such as benign panniculitis, eczema, dermatitis, cellulitis, and other skin and soft tissue infections. About three-fourths of patients with SPTCL have multifocal cutaneous involvement ( 4 ). More serious conditions associated with SPTCL include serosal eff usions, hemophagocytosis syndrome, and pancytopenia.
Imaging is useful for diagnosis and for monitoring response to therapy. Diagnosis of SPTCL is based on pathological examination of skin and subcutaneous tissue, clinical characteristics, immunohistochemistry staining patterns, and molecular analysis. Th ere are two distinct types of SPTCL based on the T-cell receptor phenotype and immunohistochemistry characteristics. Th e fi rst, T-cell receptor αβ, is characterized by an indolent, protracted course and is usually CD4 − , CD8 + , and CD56 − . Th e second, T-cell receptor γδ, is associated with rapid clinical deterioration and coexisting hemophagocytosis. It is usually CD4 − , CD8 − , and CD56 + ( 5 ) . Currently, the T-cell receptor αβ subtype is designated as SPTCL, whereas the T-cell receptor γδ is designated as cutaneous gamma/delta positive T-cell lymphoma ( 6 ) .
Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone is the preferred regimen, with overall remission rates of 50% ( 7 ) . In some cases, autologous bone marrow transplantation has been attempted. Th e overall 5-year survival rate for Tcell receptor αβ exceeds 80% ( 8 ) . Our patient received six courses of combination chemotherapy and is alive with no evidence of disease 18 months after therapy. 
